Side Effects of D-VRd in Transplant-Eligible Multiple Myeloma
The D-VRd regimen (daratumumab-bortezomib-lenalidomide-dexamethasone) causes significant hematologic toxicity, particularly neutropenia (62%) and thrombocytopenia (29%), along with infusion reactions (41%), infections (23%), and peripheral neuropathy, though the latter is less severe than with twice-weekly bortezomib schedules.
Hematologic Toxicities (Most Common)
The most frequent grade 3-4 adverse events are blood-related 1, 2:
- Neutropenia: 62.1% (grade 3-4) - the single most common severe toxicity
- Thrombocytopenia: 29.1% (grade 3-4)
- Lymphopenia: 46% (grade 3-4 in some analyses)
- Anemia: 15.9% (grade 3-4)
These rates are notably higher than VRd alone, where neutropenia occurs in 51% and thrombocytopenia in 17.3% 2.
Infusion-Related Reactions
Daratumumab infusion reactions occur in 27.7-41% of patients 3, 1. Critically, 92% of these reactions occur only with the first infusion 4. This is manageable with proper premedication protocols.
Infectious Complications
Grade 3-4 infections occur in 23.1% of D-VRd patients versus 14.7% with VRd alone 3. Upper respiratory tract infections are particularly common 1. The infection risk is amplified by:
- Neutropenia from the regimen
- Immunosuppression from dexamethasone
- CD38-mediated NK cell depletion from daratumumab 1
Prophylaxis is mandatory: herpes zoster prophylaxis for all patients on proteasome inhibitors, pneumocystis prophylaxis for those on dexamethasone, and consider levofloxacin for the first two cycles 5.
Peripheral Neuropathy
Peripheral neuropathy occurs in 24-38.6% of patients, but grade 3-4 events are uncommon (only 2-6%) 6, 7, 8. This is substantially lower than historical twice-weekly bortezomib regimens because:
- Modern protocols use weekly subcutaneous bortezomib rather than twice-weekly IV dosing
- Subcutaneous administration reduces neuropathy risk while maintaining efficacy 9
The neuropathy rate with D-VRd (46% grade 3-4) is actually lower than carfilzomib-based regimens, which cause more cardiac and renal toxicity 6.
Gastrointestinal and Constitutional Symptoms
Common but typically manageable:
- Diarrhea: 20%+ (all grades)
- Constipation: 20%+ (all grades)
- Nausea: 20%+ (all grades)
- Fatigue: 40% (all grades, 8% grade 3-4)
- Peripheral edema: 41% (all grades)
Cardiovascular and Metabolic
- Hypertension: 13% (6% grade 3-4) 1
- Hyperglycemia: 23% (from dexamethasone)
- Hypocalcemia: 14%
Notably, D-VRd has lower cardiac toxicity than carfilzomib-containing regimens, which show 4% cardiac adverse events and 16% hypertension 6.
Thromboembolic Risk
All patients require DVT/PE prophylaxis due to lenalidomide 5. Aspirin suffices for most patients, but those at higher thrombotic risk need therapeutic anticoagulation with LMWH, warfarin, or DOACs 5.
Serious Adverse Events and Mortality
- Serious adverse events: 57.0% with D-VRd versus 49.3% with VRd 2
- Treatment discontinuation due to toxicity: 23% with VRd regimens 3
- Grade 5 (fatal) adverse events: Occur but are uncommon; pneumonia and sepsis are the primary causes in older patients 6
Critical Management Considerations
Dose modifications are essential - initial dosing should be individualized based on age (especially >75 years), renal function (avoid if CrCl <40 mL/min), comorbidities, and frailty status 3.
Weekly bortezomib scheduling is now standard to reduce neuropathy 9, 7. If neuropathy develops, switch to subcutaneous administration if not already used, or consider transitioning to alternative regimens.
Stem cell mobilization: Patients receiving prolonged lenalidomide may require plerixafor for adequate stem cell collection 5.
Comparative Context
While D-VRd has more toxicity than VRd alone, it delivers superior efficacy: 84.3% progression-free survival at 48 months versus 67.7% with VRd (HR 0.42) 2. The toxicity profile is more favorable than carfilzomib-based quadruplets, which cause more dyspnea, heart failure, and acute kidney injury 6.
The benefit-to-toxicity ratio strongly favors D-VRd for transplant-eligible patients, particularly those with high-risk disease 10, 11.